StemCell Therapy

Important update: the photomedicine patent reported on here was mistakenly assigned to Apple. Inventor Dan Anderson has filed the US Patent office for a correction.

Thanks to Dan Anderson for contacting AppleInsider with copies of his correction paperwork. We are leaving the rest of the original story here as it has been widely circulated and so links back to this piece will now show the correction. For completeness, the newly corrected assignee is Topcon Medical Laser Systems Inc.

This isn't something you're going to see added to the Apple Pencil. It's not something Tim Cook is likely to announce at some future WWDC alongside an ARM Mac. But Apple's widespread, wide-scale work on health now includes research into areas more associated with hospital equipment than iPhones.

"Area scanning photomedicine device and method," US Patent No 10,617,564, is a detailed patent application which covers an extremely broad range of medical issues but chiefly does so with one purpose.

"[It is a] system and method for treating a lesion on target tissue," says the patent.

Currently, so-called superficial lesions "[meaning that] the lesion is on or near the surface of target tissue" can be treated using light. The patent lists countless applications including, for instance, photodynamic therapy (PDT) which, typically in combination with a light-sensitive drug, uses a light source to destroy cancer cells.

Light is also used in, for example, "gynecology, gastroenterology, and thoracic surgery," and Apple notes that this is far from an exhaustive list. However, Apple also notes that "although the details of the approaches vary due to the anatomical differences presented, the fundamental underpinnings are the same." And it's these underpinnings that Apple wants to address with this patent.

"[Currently] one must provide treatment light to the targeted lesion," says the patent. "To date, this has been done primarily with broad-brush application of light to the lesion and its surrounding tissue. While this has the advantage of being straightforward, it also limits the ultimate clinical efficacy by increasing the side effect profile."

In other words, the "therapies are not sufficiently site-selective," and this is a problem because the "irradiation of adjacent tissue causes more damage than is necessary." What Apple is ultimately proposing is a new system of much finer accuracy when aiming and using light treatments on lesions.

"The present invention solves the aforementioned problems by providing a multipurpose system for performing a variety of photomedical procedures that is based on contiguous scanning of a continuous wave (cw) or quasi-cw light source," claims the patent.

Apple's plan is for a device that combines different systems. It starts with a "visualization device" for "capturing an image of target tissue containing a lesion." Then when that image is acquired, it has a targeting system that combines a light source, a scanner device that can aim that light, and an overall controller.

The Apple device first captures an image that can show precisely where the boundaries of the lesion extend. Then it projects "treatment pattern onto the target tissue."

Most of the patent application's drawings are either examples of lesion patterns, or block diagrams of the combination of light source and controllers. There's no sketch of a doctor wielding an iPhone. If Apple's patent results in new hardware, it's going to be hospital-grade machinery rather than something that'll be featured in a Today at Apple store demo.

The invention is credited to Dan Anderson and David Mordaunt, each of whom have more than sixty prior patents, the majority of which are in related fields such as Anderson's "System and method for determining dosimetry in ophthalmic photomedicine," or Mordaunt's "Photomedical treatment system and method with a virtual aiming device."

Updated: 15:35 ET with new information from inventor Dan Anderson

See the original post here:
Apple investigating expansion into major health hardware [u] - AppleInsider

Global Opthalmology Pacs market offers a comprehensive analysis of the global market with in-depth and specialized analysis of the Opthalmology Pacs market. The Opthalmology Pacs market report aims to offer an extensive overview of the global Opthalmology Pacs market with broad market segmentation on the basis of products, services, application, as well as regional overview. In addition, the Opthalmology Pacs market report also provides a complete analysis of the global market trends that are influencing the global market over the forecast period.

Top Leading Key Players are:

Topcon Corporation, IBM corporation, Carl Zeiss Meditec AG, EyePACS, Heidelberg Engineering and more.

Get Sample Copy of this Report: https://www.adroitmarketresearch.com/contacts/request-sample/608

The Global Opthalmology Pacs market largely focuses on prominent facets such as product portfolio, payment channels, service offerings, applications, in addition to technological sophistication. This comprehensive research- documentary on global Opthalmology Pacs market is a holistic perspective of market developments, factors, dynamics, trends and challenges that decide growth trajectory of global Opthalmology Pacs market. The report lends versatile cues on market size and growth traits, besides also offering an in-depth section on opportunity mapping as well as barrier analysis, thus encouraging report readers to incur growth in global Opthalmology Pacs market.

Moreover, the global Opthalmology Pacs market is likely to witness a significant growth over the forecast period. Additionally, the global Opthalmology Pacs market report offers a comprehensive analysis of the major service providers impacting the market are also profiled in the report. The global Opthalmology Pacs market provides the detailed market strategies as well as other significant data about the market with their SWOT analysis.

Browse the complete report @ https://www.adroitmarketresearch.com/industry-reports/opthalmology-pacs-market

Global Opthalmology Pacs market is segmented based by type, application and region.

Based on Type, the market has been segmented into:

By End-Use, market is segmented into:

HospitalsAmbulatory Surgical Center (ASCS) & Specialty ClinicsOthersBy Type, market is segmented into:

Standalone PACSIntegrated PACSBy Delivery Model, market is segmented into:

Cloud/ web based modelsOn-premise modelsOthers

The report is rightly designed to present multidimensional information about the current and past market occurrences that tend to have a direct implication on onward growth trajectory of the Opthalmology Pacs market. The report specifically focuses on market drivers, challenges, threats, and the like that closely manifest market revenue cycle to encourage optimum profit generation in the Opthalmology Pacs market.

In addition to this, the target market report provides inclusive analysis of the SWOT and PEST tools for all the major regions such as North America, Europe, Asia Pacific, and the Middle East and Africa. The report offers regional expansion of the industry with their product analysis, market share, and brand specifications. Furthermore, the Opthalmology Pacs market study offers an extensive analysis of the political, economic, and technological factors impelling the growth of the global Opthalmology Pacs market across these economies.

For Any Query on the Opthalmology Pacs Market: https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/608

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Read more from the original source:
Opthalmology Pacs Market 2020 Global Share, Growth, Size, Opportunities, Trends, Regional Overview, Leading Company Analysis, And Key Country Forecast...

Israeli-based Pluristem has treated its first American patient suffering from COVID-19 complications under the countrys compassionate use program.The news comes days after a report by the company showed that six critically ill coronavirus patients in Israel who are considered high-risk for mortality were treated with Pluristems placenta-based cell-therapy product and survived, according to preliminary data provided by the Haifa-based company.In the US case, the patient was treated with the companys PLX cell therapy at Holy Name Medical Center in New Jersey, where Pluristem is already running a Phase III critical limb ischemia study. Like the patients treated in Israel, this patient was critically ill with respiratory failure due to acute respiratory distress syndrome and was intubated in an intensive care unit for three weeks.The companys president and CEO, Yaky Yanay, said that although Pluristem is focused on a planned multinational clinical trial for the treatment of complications associated with coronavirus, it does hope to expand treatment under compassionate use in other countries at the same time.

Specifically, the US treatment was administered under the US Food and Drug Administrations Single Patient Expanded Access Program, which is part of the US Coronavirus Treatment Acceleration Program - an emergency program aimed at getting treatments to corona patients as quickly as possible.

In Israel, the six patients were treated at three different Israeli medical centers for one week, also under a compassionate use program. They were suffering from acute respiratory failure and inflammatory complications associated with COVID-19. Four of the six patients also demonstrated failure of other organ systems, including cardiovascular and kidney failure.

Pluristems PLX cells are allogeneic mesenchymal-like cells that have immunomodulatory properties, meaning they induce the immune systems natural regulatory T cells and M2 macrophages, the company explained in a previous release. The result could be the reversal of dangerous overactivation of the immune system. This would likely reduce the fatal symptoms of pneumonia and pneumonitis (general inflammation of lung tissue).

Previous preclinical findings regarding PLX cells revealed significant therapeutic effects in animal studies of pulmonary hypertension, lung fibrosis, acute kidney injury and gastrointestinal injury.

We are pleased with this initial outcome of the compassionate use program and committed to harnessing PLX cells for the benefit of patients and healthcare systems, Yanay said.

View post:
Israeli COVID-19 treatment with 100% survival rate tested on US patient - The Jerusalem Post

After an active Sunday, cooler and quieter temperatures are expected for much of the week ahead. In fact, thermometers could dip into the 40s a few mornings!

Sunday Storm Report: An outbreak of severe weather did indeed occur across the Gulf South on Sunday. The local area was largely spared as the outlook and atmosphere changed for the better in the local area. This change was identified and broadcast by the WBRZ Weather Team on Sunday morninga reminder that it is important to stay in touch with the forecast as events near because changes can and do occur; in this case, it was good news. Still there were a few severe weather reports, including damaging wind gusts in Springfield and large hail in Hammond. Several large, violent tornadoes ripped through southeast Mississippi.

THE FORECAST:

Today and Tonight: Drier and cooler air will continue moving into the local area, allowing clouds to rapidly diminish through the morning hours. This will lead to sunny skies into the afternoon with high temperatures peaking near to 76 degrees. Remaining all clear overnight, light northeast winds will guide low temperatures down to 53 degrees.

Up Next: Through much of the week, highs will stay near normal in the mid-to-upper 70s. A rebounding weak warm front will attempt to push onshore Tuesday, which could bring some spotty afternoonshowers into the mix between during the late afternoon and overnight hours. The best chance of finding a shower will be in coastal areas. Once this front kicks to the south, continued cool temperatures could result in a pair of overnight lows in the upper 40s. Showers are set to return closer to the weekend. These will be associated with a frontal systemthat should bring isolated afternoon storms on Saturday that become more scattered in nature by Sunday.

The Mississippi River: At Baton Rouge, major flood stage continues with a level of 42.8 as of Monday morning. The river is expected to fall very slowly through the next two weeks. The high water is primarily an issue for river traffic and river islands, although some inundation will continue for a few spots north and south of Baton Rouge that are not protected by levees. Unprotected low-lying areas will be flooded and agricultural operations will be impacted on the west side of the river. The grounds of the older part of Louisiana State University's campus become soggy. This includes the area around the Veterinary Medicine building, the Veterinary Medicine Annex, the stadium and ball fields. The city of Baton Rouge and the main LSU campus are protected by levees at this level. The level is also high in New Orleans and the U.S. Army Corps of Engineers has opened the Bonnet Carre Spillway.

THE EXPLANATION:

The front associated with Sundays active weather will stall in the Gulf of Mexico on Monday, retreating slightly north on Tuesday. The may serve as a focus for a few showers to develop on Tuesday afternoon through the overnight hoursespecially along the coast. A kicker front will flush this moisture south by Wednesday and the cooler air mass will become entrenched a little farther south. As a result, the coolest period of the week is expected Wednesday morning through Thursday afternoon with lows in the upper 40s and highs in the low 70s. The next frontal system will organize across the Lower Midwest and begin ton affect the local area by Friday. A slow moving warm front could provide isolated showers on Friday and Saturday and the trailing cold front will result in a better chance for showers and a few thunderstorms by Sunday.

--Josh

The WBRZ Weather Team is here for you, on every platform. Your weather updates can be found on News 2, wbrz.com, and the WBRZ WX App. on Apple and Android devices. Follow WBRZ Weather on Facebook and Twitter for even more weather updates while you are on the go.

See the article here:
Below average temperatures, quieter weather ahead - WBRZ

Press release: Pet Industry Joint Advisory Council

There have been reports of early stage research on the antiparasitic drug ivermectin as a possible treatment for COVID-19.

In animal health, ivermectin is most commonly used as a heartworm preventive in dogs and cats, and well as for treating internal and external parasites in many species.

On behalf of the entire responsible pet care community, we warn the public that they should never use pet care products, or any products, for any purpose other than what the label directs. Products marketed for veterinary use or otherwise not for human consumption should never be ingested or used for self-treatment of COVID-19 or any human medical condition.

The Food and Drug Administration (FDA) Center for Veterinary Medicine has issued a letter to stakeholders warning against humans using ivermectin products intended for animals. FDA is concerned about the health of consumers who may self-medicate by taking ivermectin products intended for animals, thinking they can be a substitute for ivermectin intended for humans. People should never take animal drugs, as the FDA has only evaluated their safety and effectiveness in the particular animal species for which they are labeled. These animal drugs can cause serious harm in people. People should not take any form of ivermectin unless it has been prescribed to them by a licensed health care provider and is obtained through a legitimate source.

FDAs recommendations:

The FDA has established a cross-agency task force dedicated to closely monitoring for fraudulent COVID-19 products that reaches out to major retailers to ask for their help in monitoring online marketplaces. Products that claim to prevent, diagnose, treat, or cure COVID-19 are subject to FDA investigation and potential enforcement action if they have not demonstrated safety and effectiveness for that intended use. The task force has already worked with retailers to remove dozens of these types of product listings online.

Please help us protect public health by alerting FDA of anyone claiming to have a product to prevent or cure COVID-19 and to help safeguard human and animal health by reporting any of these products toFDA-COVID-19-Fraudulent-Products@fda.hhs.govor 1-888-InfoFDA (1-888-463-6332).

The most effective ways to protect yourself and others against COVID-19 are to avoid being exposed to the virus and taking steps to protect yourself as recommended by CDC:

For the latest information and resources about how to protect yourself, your customers, your associates and the animals you care for; mandatory closure orders as they pertain to pet care businesses; and other health and business continuity resources please visitpijac.org/covid19.

Continued here:
PIJAC Warns About Using Ivermectin to Treat COVID-19 - Pet Age

Immunotherapies have revolutionized treatment for people with a variety of cancers. But when given to those with triple-negative breast cancer (TNBC), a particularly aggressive form of the disease, less than 20% respond.

A big question in the field has been, Why are the rest not responding? says Rumela Chakrabarti, an assistant professor at Penns School of Veterinary Medicine.

In a new paper in Nature Cell Biology, Chakrabarti and colleagues illuminate the molecular details at play. They found a signaling pathway which could be exploited in TNBC patients to better target therapies in the future. Using a mouse model of the disease that mimics key characteristics of human disease, they showed that losing the activity of the protein ELF5 promotes the activity of another protein, interferon-gamma receptor 1. Stabilized Interferon-gamma receptor 1 leads to activated interferon gamma signaling, which in turn leads to increases in tumor aggression and spread, which could be mitigated with therapeutics that block interferon gamma signaling.

This was an eye-opener, says Chakrabarti, because often interferon gamma has a protective effect in cancer and is commonly given as a cancer therapy to some patients. It works well in certain cancer types, but for particular subtypes of triple-negative breast cancer we see that blocking interferon gamma may be the best strategy for patients.

Chakrabarti had a deep familiarity with the biology of the ELF5 protein. She began studying it more than a decade ago as a postdoctoral researcher at the State University of New York at Buffalo, finding that its normal function supported pregnancy and lactation. More recently, in 2012 she and colleagues published a previous report in Nature Cell Biology showing that ELF5 could suppress a key transition that occurs to enable breast cancers to spread.

That earlier work, however, did not focus on TNBC specifically, in part because scientists had lacked an effective mouse model. Over the course of three years, Chakrabartis team developed a preclinical TNBC model that recapitulated two hallmarks of the disease: its propensity to spread and the influx of immune cells that accompanies tumor growth.

In the current study, the researchers found that, when these TNBC mices tumors also lost the function of the ELF5 protein, their disease course resembled that of human patients even more closely. Losing ELF5 made the disease very metastatic and very aggressive, says Chakrabarti.

To elucidate the molecular happenings that resulted in a more dangerous form of TNBC, Chakrabarti and colleagues examined the RNA that was being expressed in tumor cells of the TNBC mice whose tumors lost ELF5 expression. They found increased activity of the interferon-gamma pathway, caused, they believe, by an increase in expression of that proteins receptor. This loss also led to an accumulation of neutrophils, a type of immune cell, which has immune suppressive function. In contrast, normal mammary cells that retained ELF5 had low levels of interferon gamma signaling.

Blocking this signaling using an antibody against the interferon gamma receptor 1, or by genetically manipulating tumor cells to express lower levels of the receptor caused tumors to grow and spread more slowly.

Finally, to determine whether these findings in a mouse model may be relevant to humans, the research team looked at genetic and protein data from patients to determine their level of ELF5 and interferon gamma receptor expression. Patients with lower ELF5 and higher receptor levels, they observed, fared poorer; their cancers tended to spread sooner around their bodies.

The findings, Chakrabarti says, should be considered carefully by clinicians who are using interferon gamma and immunotherapies to treat cancer patients.

This is telling us that we need to target patients more selectively when we treat them, says Chakrabarti. It could be that if someone has low ELF5, they should be given an interferon-gamma signaling blocking therapy in addition to their immunotherapy.

In future work, Chakrabartis group will be diving in deeper into the immunology of TNBC, examining the role that different immune cells are playing in driving cancer metastasis and aggression. They also hope to see whether what they found regarding interferon gamma signaling in TNBC holds true in other tumor types, such as kidney and ovarian cancers.

Rumela Chakrabarti is an assistant professor of biomedical sciences at the University of Pennsylvania School of Veterinary Medicine.

Chakrabartis coauthors on the paper were first author Snahlata Singh, Sushil Kumar, Ratnesh Kumar Srivastava, Ajeya Nandi, Gatha Thacker, Hemma Murali, Sabrina Kim, Mary Baldeon, Mario Andres Blanco, and Serge Fuchs of Penn Vet; John Tobias, Rizwan Saffie, and Luca Busino of Penn s Perelman School of Medicine; Temple Universitys M. Raza Zaidi; and Satrajit Sinha of the State University of New York at Buffalo.

The work was supported by the National Cancer Institute (grants CA193661 and CA237243).

Excerpt from:
Tailoring treatment for triple-negative breast cancer - Penn: Office of University Communications

In light of COVID-19 and the associated restrictions on public activity, many people are looking for ways to safely go about their daily lives indoors and online. Luckily, telemedicine supports this goal and allows individuals to ensure their health and the health of their pets, digitally.

Dog laying its head on a keyboardDr. Lori Teller, a clinical associate professor at the Texas A&M College of Veterinary Medicine & Biomedical Sciences, speaks to pet owners about the basics of veterinary telemedicine and how this tool can be especially useful in the midst of a pandemic.

Telemedicine is the exchange of medical information from one location to another using electronic communications to diagnose, treat, or improve a patients health status, Teller said. In most cases, all that an animal owner needs to connect is a smartphone with a working camera, microphone, and chat feature.

A computer or tablet may also be used, provided that it is capable of two-way communication and has internet access. In many cases, a telemedicine appointment will be a real-time, live video and audio exchange.

A veterinarian can evaluate many things via telemedicine, Teller said. The first thing will be to obtain a patients history and determine what the current problem is. If the problem is something that can be visualized, such as a skin lesion or limping, then pictures or videos will be helpful. Behavioral and nutritional problems can often be handled via telemedicine as well.

Telemedicine appointments are most effective when there is an established veterinarian-client-patient relationship (VCPR), as the veterinarian may be able to more accurately make a diagnosis and create a treatment plan. If there is no established VCPR, a veterinarian will still be able to provide general advice. Rules on what the outcome of a telemedicine appointment can be, including the prescription of medications, vary by state.

It is important to note that telemedicine does not replace a physical exam, so there will be times when the veterinarian will tell the client that the patient needs to be seen, Teller said.

Story continues below video

Telemedicine can play a huge role, especially in times of disaster, such as a pandemic or hurricane, in helping a client determine if a trip to the veterinarian is needed and, if so, when is it needed.

If a pet has a life-threatening emergency, difficulty breathing, pale or bluish gums, has ingested a toxic substance or something large enough to cause an obstruction, is unable to urinate or to stand, has increased seizures, is non-responsive, is experiencing difficulty during labor, has vomiting and diarrhea and lethargy, or is experiencing other serious veterinary conditions, they should be brought to a veterinary clinic.

Teller recommends calling ahead of time to let the clinic know youre coming and what the problem appears to be.

Telemedicine is an extremely valuable tool to help provide care for a patient, she said. It is not a substitute for in-person veterinary care that requires a physical exam or diagnostic tests, such as blood work or imaging, but is a way to manage patients in-between visits to the hospital.

During times of disruption, such as the current pandemic, telemedicine can be an excellent way to ensure that your furry friend continues to get the care they need while also following social distancing requirements and staying safely indoors.

Telemedicine is especially valuable during a pandemic because it can be used to help the veterinarian and the client determine if and when the patient needs to be seen in the hospital or if the problem can be managed at home, at least for the short term, Teller said. It also helps conserve PPE (personal protective equipment) and other resources for emergencies and for human health care facilities.

Pet Talk is a service of the College of Veterinary Medicine & Biomedical Sciences, Texas A&M University. Stories can be viewed on the web at vetmed.tamu.edu/news/pet-talk. Suggestions for future topics may be directed to editor@cvm.tamu.edu.

We are making critical coverage of the coronavirus available for free. Please consider subscribing so we can continue to bring you the latest news and information on this developing story.

Go here to see the original:
PET TALK: Veterinary telemedicine in the age of COVID-19 - New Castle News

Kaitlin Sisk grew up in the town of Erie, Colorado on what she calls a four-acre "family hobby farm." Her mom is a fiber artist, so they had lots of pets including angora rabbits and cashmere goats, and Sisk had her own horse.

Growing up with furry friends helped Sisk focus in on a career path.

"I think it just sort of like fell in my lap," she said. "It just seemed easy to me being around animals and working with them."

The 31-year-old is in her final year of pursuing a Doctor of Veterinary Medicine degree at Colorado State University in Fort Collins. She's studying small animals. In mid-March the veterinary teaching hospital moved all of its classes online.

"That's easy to do for some of those didactic lectures, you know, maybe not as good," said Felix Duerr, a professor who works at the hospital. "If you have a class of a hundred thirty something in front of you, you know, you can do that online as well."

The veterinary medicine program also put medical cases online and created other tools that will be useful to students even after the pandemic ends. This includes conducting daily rounds, where students meet as a group to discuss cases, virtually.

"We would just sit in front of a computer and be like, 'hey, can you point at where you see the abnormality that we're concerned about,''' said Duerr. "Now we just do that online and everybody can do it at the same time."

But the hands-on part of the program is more difficult to duplicate digitally. Take a dog that has lameness, said Duerr. A student can't feel if the knee is warmer or has instability on a computer.

"So that's probably our biggest challenge I would say," he said.

Not only have classes moved online, but the hospital staff is now using telemedicine to treat animals with non-emergency illnesses.

Theresa Wendland is a third-year sports medicine and rehabilitation resident. She uses video to to examine animals and consult with their owners. One of her patients is Oliver, a six-year-old poodle with a torn Achilles tendon.

"I've never done a distance fitting before so I'm going to apologize a little bit here that it might be a little trial and error," Wendland said during the video chat.

Before the statewide stay-at-home order, Oliver was diagnosed in person and a custom brace was ordered for him. But once the hospital closed to non-emergency patients, the brace was shipped to the dog's owner. On the video, Wendland shows her and a friend how to put it on Oliver.

"Move your hand up and give the pad a little squeeze. So that you're squeezing the pad onto his foot. There you go," she said. "Then you're pulling that strap snugly across his foot."

Wendland was a CSU veterinary medicine student and remembers the importance of hands-on clinical rotations. She worries current students are going to miss out on valuable experiences.

"So, we're trying to find ways to teach while also still providing services and help to owners and their pets," Wendland said.

Fourth-year student Kaitlin Sisk is still learning a lot online. She's on a two-week orthopedic rotation and watched Oliver get his brace then walk to make sure the fit was right.

"We still could do like a lot of what they were going to do. It's just it's harder when you can't put your hands on it," said Sisk. "But I think it's still working."

Sisk agrees that it's hard to get clinical hands-on training online. Students watch consults and surgeries remotely and study interactive videos. But Sisk has found a way to get practical experience.

"I think I'm lucky because I have a cat and a dog so I can kind of like go through the video and pause it and palpate my dog and and then keep going," she said. "I think it is like a little bit more active learning, like you have to be motivated to do it."

Overall, remote learning hasn't been too bad for Sisk. Since she can't spend her days in the hospital, she's going outside and exercising more.

Sisk is an extrovert. She worried about being stuck at home and not interacting with the people in her program. But something unexpected happened she feels a lot closer to them now.

"I know that it's kind of weird because you'd think that you wouldn't feel close to them when you're sitting in opposite houses. But like you see their house, you see their animals come up behind them and come say hi," she said. "So, it feels like you get to see a little piece of them and their family, which I think it's something we don't really get at school. We're all business."

Sisk is graduating in May. Then she's planning to move and start a job at an animal hospital in Boulder. But when it comes to mapping out the next couple months, Sisk said, "we'll see what happens."

Original post:
Online Courses And Virtual Consults: CSU Vet Teaching Hospital Adapts To Coronavirus - KUNC

Chamberlain University partners with Ascend Learnings ATI Nursing Education business to offer a free course in acute care

As healthcare organizations continue to respond to the COVID-19 pandemic, hospitals and clinics are calling on nurses from all specialties to fill this critical need. To help those practitioners prepare for direct acute patient care, Chamberlain University, in partnership with Ascend Learning, is offering a free online course for all licensed registered nurses.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200413005115/en/

"As the COVID-19 pandemic sweeps the country, I am in awe of the nursing community as it steps forward in the face of crisis," said Karen Cox, Ph.D., RN, FACHE, FAAN, president of Chamberlain University. "Nurses who havent practiced in acute care recently want to jump in, and hospital leaders want to equip all of their nurses to work on the front lines. As a nurse and an educator, I am honored to assist these healthcare workers in the face of a crisis."

Acute Care Readiness is a review course that is not for academic credit. It covers the knowledge and skills nurses need to help them return to safe clinical practice in acute care settings. These skills include patient assessments, medication administration and complex acute care procedures. Ascend Learning will partner with Chamberlain University to provide online educational expertise.

"As the need and call for more qualified frontline nurses continues to grow, we want to help. We are thankful we can offer free resources to support these courageous and selfless healthcare workers through our ATI Nursing Education solutions as they sharpen their critical care skills and respond to the call to help save lives," said Ascend Learning CEO, Greg Sebasky.

Licensed RNs who may have been working in ambulatory care, long-term care or in non-acute care roles as advanced practice registered nurses (APRNs) would benefit from this course. To learn more about the Acute Care Readiness course, contact Chamberlain Universitys director of professional development at CFE@chamberlain.edu.

This partnership responds to the demand for acute care skills in the U.S. at scale in a manner that can be impactful. This is aligned with Chamberlain Universitys parent company, Adtalem Global Education, in its mission to provide workforce solutions and make positive contributions to the global healthcare community. According to the U.S. Department of Educations most recently published data, Adtalem, through its affiliated schools of Chamberlain University, American University of the Caribbean School of Medicine and Ross University School of Medicine, educates and graduates more doctors and nursing professionals than any other individual school in the U.S. Ascend Learnings ATI Nursing Education business is a leading provider of online instruction for nursing schools across the United States with 98% of nurse educators naming it a leader in the nursing education industry and 93% claiming ATIs solutions improved their students ability to perform as a new nurse, according to a 2019 research solutions survey.

About Chamberlain University

Chamberlain University is a part of Adtalem Global Education (NYSE: ATGE). Chamberlain Universitys mission is to educate, empower and embolden diverse healthcare professionals who advance the health of people, families, communities and nations. Chamberlain University is comprised of the College of Nursing, which offers a three-year Bachelor of Science in Nursing degree program and flexible post-licensure programs such as the RN to BSN online option, Master of Science in Nursing degree program, Doctor of Nursing Practice degree program and graduate certificates, and the College of Health Professions, which offers a Master of Public Health and Master of Social Work degree programs. Chamberlain University is accredited by the Higher Learning Commission http://www.hlcommission.org, a regional accreditation agency recognized by the U.S. Department of Education. For the most updated accreditation information, visit chamberlain.edu/accreditation. To learn more, visit chamberlain.edu.

About Adtalem Global Education

The purpose of Adtalem Global Education is to empower students to achieve their goals, find success, and make inspiring contributions to our global community. Adtalem Global Education Inc. (NYSE: ATGE; member S&P MidCap 400 Index) is a leading global education provider and the parent organization of Adtalem Educacional do Brasil (IBMEC, Damsio and Wyden institutions), American University of the Caribbean School of Medicine, Association of Certified Anti-Money Laundering Specialists, Becker Professional Education, Chamberlain University, EduPristine, Ross University School of Medicine and Ross University School of Veterinary Medicine. For more information, please visit adtalem.com and follow us on Twitter (@adtalemglobal) and LinkedIn.

Story continues

About Ascend Learning

Ascend Learning is a leading provider of online educational content, software and analytics serving students, educational institutions and employers. With products that span the learning continuum, Ascend Learning focuses on high-growth careers in a range of industries, with a special focus on healthcare and other high-growth, licensure-driven professions. Ascend Learning products, from testing to certification, are used by frontline healthcare workers, physicians, emergency medical professionals, nurses, certified personal trainers, financial advisors, skilled trades professionals and insurance brokers all along the learning continuum from student through the lifetime career professional. ATI Nursing Education, an Ascend Learning business, uses progressive data analytics and compelling content to help nursing students master core curriculum, develop into a practice-ready nurse, and succeed on the NCLEX. Learn more at http://www.ascendlearning.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200413005115/en/

Contacts

Media Contacts: Elizabeth Story815.545.4242Elizabeth.Story@adtalem.com

Rachel Durbin816.529.3134Rachel.Durbin@ascendlearning.com

Originally posted here:
Chamberlain University and Ascend Learning launch course to help nurses prepare for COVID-19 care - Yahoo Finance

CHICAGO As the number of confirmed COVID-19 cases continues to surge worldwide, scientists and health experts, including University of Illinois researchers who helped diagnose a New York zoo tiger with the disease, are now looking into how animals are affected by the new coronavirus.

Earlier this week, the Bronx Zoo revealed that a 4-year-old Malayan tiger tested positive for the new coronavirus after she and six other tigers and lions developed a dry cough. And despite the tiger and a few other animals abroad testing positive for the virus, health officials are dispelling fears that people can contract COVID-19 from their pets.

Theres no evidence that pets, including cats and dogs, can spread COVID-19 to people, said Dr. Casey Barton Behravesh, director of the Centers for Disease Control and Preventions One Health Office in the National Center for Emerging and Zoonotic Infectious Diseases.

Barton Behravesh noted that there was no reason to think that the skin or fur of pets can spread the virus to people.

But while health experts say there is no evidence to suggest pets can transmit coronavirus to humans, they are encouraging people who have the disease or are exhibiting symptoms of COVID-19 to remain socially distant from their pets.

If somebody has been diagnosed with COVID-19 in a household, or they have been exposed to someone who was and are in quarantine, they should treat their pet just like any other human in their family, said Dr. Rustin Moore, the dean of Ohio State Universitys College of Veterinary Medicine.

He added, that means maintaining social distancing, no touching, petting, cuddling, or hugging.

Dr. Karen Terio, the chief of the Zoological Pathology Program at the University of Illinois veterinary college, where tests for the Bronx Tiger were done, said she and other scientists are now looking at what other types of animals are susceptible to the virus.

Were trying to understand how this virus might be spread or transmitted between different animal species. and how it might be spread between humans and animals, she said.

Its possible wild cats might be more susceptible to COVID-19 than domestic cats, as other viruses can hit wild cats hard, but not affect domestic cats as much, according to the University of Illinois. But its not yet known what differences there might be in the effect of COVID-10 on house cats and wild cats.

To date, a large number of humans have been infected by the virus and become sick and many people have pet cats, Terio said. The fact that the first confirmed case in an animal in the United States is from a tiger suggests that even among cat species there may be differences in susceptibility to the virus.

Barton Behravesh said the CDC is not recommending routine pet testing.

We dont want a lot of people rushing out to veterinary clinics right now trying to get their pets tested; that would increase the exposure, she said.

Theres a strict criterion that must be met before an animal can get tested by a veterinary lab, Terio said.

Just because we have a test doesnt mean well accept samples from anybodys cat or dog, she said. There has to be approval at multiple levels between both animal and public health officials to have an animal tested.

The Anti-Cruelty Society started reducing their animal population weeks ago in anticipation of needing more cage space to help people across the Chicagoland area who may be quarantined or hospitalized because of COVID-19.

Weve spent the last several weeks preparing for the upcoming weeks to make sure that we have the capacity to have a safe place for peoples animals to go, said David Dinger, vice president of operations for the Anti-Cruelty Society.

And the Anti-Cruelty Societys efforts have been successful.

The societys animal population has reduced from roughly 600 animals to 135 in the last few weeks, Dinger said, which has freed up hundreds of slots for pets that may need a home while their owner has COVID-19.

See the article here:
With Bronx Zoo tiger catching coronavirus, should pet owners be concerned about COVID-19? Health experts weigh in - Greater Milwaukee Today

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

View original post here:
USDOL Issues Opinion Letter On Inclusion of Longevity Bonus In The Regular Rate - JD Supra

Recessions save lives. This statistical truth has been a thorn in the side of capitalism and neoliberalism, and a befuddling conundrum for economists and sociologists. This conveniently ignored inconvenient truth has been the subject of much investigation, but none of the umpteen interdisciplinary studies probing the enigma have yielded substantial or convincing insight.

Perhaps the ideological perturbation posed to the Western world by this fact has held back its evaluation economic inequality. However, the advocates of economic booms have little to worry about unless theyre plutocrats. In the long term, the positive relationship between economic growth and longevity is well established.

A lot of reputable research literature exists depicting a just-as-consistent and certain association of periods of recessions with increased longevity. However, a similar volume of counter-indicative literature exists that criticizes the formers methodologies, proposes a lagging causality (delayed materialization of effects) of macroeconomic cycles and phases with life expectancies.

Even articles published in the worlds premier scientific journal Nature are divided on the issue. However, what we can be sure of is that every major recession period has been accompanied by a conspicuous decline in mortality rates.

The fact that notable recession events have gone hand-in-hand with conspicuously lower mortality rates has been known ever since William Ogburn and Dorothy Thomas, sociologists at New Yorks Columbia University, analyzed 50 years worth of US economic and mortality data. The duo, being seasoned and keen researchers, were wary of mistaking mere correlation for causality a classic attributive fallacy.

They inspected two probable pitfalls a possible lag between economic downturn and rise in deaths, that is, whether the adverse health effects of scarcity took effect after a while, and if documentation of deaths was more discreet and meticulous during booms. Their further scrutiny categorically ruled both of these out. Eminent social epidemiologist Edgar Sydenstricker wrote to the US Public Health Service in 1933, at the beginning of the Great Depression. Other major recession events follow suit.

According to statistics from the International Labor Organization, around 2.3 million people succumb to work-related accidents or diseases every year. ILO data also show that 340 million occupational incidents transpire annually, while 140 million victims suffer from occupation-related ailments.

Injuries claimed almost 5 million lives in 2016, about 30% of which were in road/traffic-related accidents, according to statistics presented as part of the Global Health Estimates by the World Health Organization.

In the same data, once can observe that the respiratory ailments chronic obstructive pulmonary disease, lower respiratory infection, and cancer of the trachea, bronchus or lungs are three of the leading causes of death, consistently featuring in the top 10 places, with the former occupying two of the top five spots, year after year. Many of these cases are caused or contributed to by two man-made factors: pollution and chronic smoking. Smoking results in about 8.2 million deaths annually.

On the issue of air-pollution-related mortality, the WHO says, The combined effects of ambient (outdoor) and householdair pollutioncause about 7 million prematuredeaths every year, largely as a result of increasedmortalityfrom stroke, heart disease, chronic obstructive pulmonary disease, lung cancer and acute respiratory infections. The latest research puts it at 8 million.

Pollution and smoking can aggravate existing ailments and weaken the natural recuperative ability and tenacity of respiratory system exposing them to greater jeopardies and increased risks of complications posed by other respiratory ailments. Recent research published in Cardiovascular Research found that air pollution reduces average human life expectancy by three years (for comparison, smoking takes off 2.2 years) and put the annual toll for 2015 at 8.8 million. Water pollution caused 1.8 million deaths in the same year.

During the current Covid-19 pandemic, strict lockdowns are averting workplace accidents, preventing narcotic consumption, reducing vehicular and industrial pollution, and precluding transport-related fatalities. These are the same factors that contribute to a lowering of mortality rates during recessions.

Moreover, less work during recessions also very often translates to more sleep, better diet (carefully home-cooked, balanced and nutritious), less work-related stress, and more opportunity for exercise, leading to amelioration of cardiovascular problems.

Having less money to spare also lowers the consumption of cigarettes and alcohol. Having more time to dedicate to leisurely, creative or recreative pursuits and being with family could also enhance bodily and mental integrity and extend lifespans.

All these factors are currently being amplified during strict nationwide stay-at-home quarantines. Of course, the increased chance of deaths in home accidents such as falling-related injuries, fires, and suffocation should be factored in this. Nevertheless, a protracted and largely unrelenting lockdown is bound to reduce the death rate, given that it eliminates the scopes of multiple leading causes of death.

Economists have foreseen a watershed recession for more than a month now it is now more of a matter of when than if, while some suspect it has already begun. The pandemic has impeded and obstructed supply-chain flows, upset supply-demand equilibria, and incapacitated resource procurement and most forms of production. Social distancing and lockdowns have adversely affected the economy.

Not only does a lockdown exert the same, and more pronounced, effects on longevity as a recession does, but it also leads to recession itself. There is an increase in mortality caused by the disease competing with an increase in longevity caused by industrial, technological and economic incapacitation together these determine the influence of the crisis on life expectancy. There thus exists an optimal point, a sweet spot, for life expectancy that lies at the intersection of primarily three interplaying factors: the extent of the spread of Covid-19, the longevity extension caused by preventive measures, and the longevity extension due to the recession caused thereby.

Of course, the human socioeconomic and political-policy response to it, the lingering of disease-related apprehension, the persistence of precaution, and the permanence of institutional change it ushers in, will determine its specifics. The pandemic is expected to leave a lasting impact not only practically and institutionally but also normatively, ideologically, and psychologically. Hence it would not be an overstatement to say that there might just exist a silver lining amid this morbid semblance, just not a very conspicuous one.

The very existence of this rather obscure bright side depends on how we deal with the epidemic the spread, the mortality rate, and the flattening of the curve the pivotal sweet spot is the fulcrum of the teetering see-saw of demographics, either end of which dips into decrement.

However, the key takeaway is not the greater good or some statistical satisfaction, but a realization of how neglectful we are of threats non-acute in nature those as ubiquitous, sizable and as invisible as the coronavirus, that result from our own actions yet occur so unsystematically and regularly that we stay blissfully ignorant of them. Omnipresent slow killers such as pollution and smoking abound in our world, yet we casually tuck them away in a conveniently remote recess of the mind, informed yet tantalisingly unaware.

Let us not derive a figment of solace and consolation from the salubrious effects of the pandemic but acknowledge the multitude of equally sizaable and pressing hazards that our daily environments abound in, that just happen to be exposed by a competing, more conspicuous and acute threat.

Asia Times Financialis now live. Linking accurate news, insightful analysis and local knowledge with the ATF China Bond 50 Index, the world'sfirst benchmark cross sector Chinese Bond Indices.Read ATFnow.

See the rest here:
Recessions, longevity and the Covid-19 sweet spot - Asia Times

Longevity has played a part in the selections of some of our top 10 Bruins of all-time, but had nothing to do with us choosing Phil Esposito at No. 3 on our list.

He arrived via a trade in 1967 and left the same way in 1975 both deals whoppers for the ages that would have major impacts on the organization. In between he played just 625 games in Black and Gold, the fewest of any modern era skater other than Cam Neely on our list.

But in those eight-plus seasons in Boston, Esposito was the catalyst for the most explosive offensive juggernaut the league had seen to that point and was one of the great characters of arguably the most beloved team in Bostons rich sports history.

In the spring of 1967, the Bs already had a kid in Bobby Orr who would become the greatest defenseman in NHL history and, yes, here in Boston still the greatest player ever but hockey is all about depth. That was provided when the Bs incoming GM Milt Schmidt pulled off a heist, sending forward Pit Martin, defenseman Gilles Marotte and goalie prospect Jack Norris to Chicago for Esposito, Fred Stanfield and Ken Hodge.

Martin would be a mainstay on a very good Blackhawks team, Marotte bounced around the NHL for 10 more years and Norris played 35 more NHL games.

Esposito made the Bruins a cultural phenomenon.

In Chicago, the Blackhawks had the top goal-scorer in the league at that time in Bobby Hull. His centerman Esposito was primarily Hulls playmaker, but that perception would be irrevocably shattered in short order when he arrived in Boston.

Esposito became the first player to break the 100-point mark in a season, posting 49-77-126 totals in 1968-69. As a team, they would finally break through the next year, winning the Stanley Cup for the first time in 29 years.

The next regular season was not only his finest, but the best the league had ever seen from a forward to that point. On March 11, 1971, Esposito, parked in his usual spot in the slot, redirected a Ted Green shot for his 59th goal of the season in a rout of the Los Angeles Kings in the then-Great Western Forum, breaking his former linemate Hulls record of 58.

But he didnt stop there. Esposito potted 76 goals that year, along with 76 assists for 152 points (another record at the time) in 78 games. With linemates Wayne Cashman and Ken Hodge comprising a first line that was impossible to contain, Esposito would hold the records for most goals and points for another decade until Wayne Gretzky came along and rewrote the book. Esposito captured the Art Ross Trophy five times in his eight full seasons with the Bs while Orr won it twice in that time, keeping the award in Boston seven straight seasons (Chicagos Stan Mikita won the award in 1967-68).

While Orr won the Conn Smythe Award as playoff MVP in the Cup seasons of 70 and 72, Esposito was no slouch in the postseason. In the first Cup season he posted 13-14-27 totals in 14 games and in the second Cup run he had 9-15-24 in 15 games. In 71 playoff games with the Bruins, Esposito notched 46-56-102 totals. His 1.437 points per playoff game average is second only to Barry Pedersons 1.529 (20-32-52 in 34 games).

Through all those wild times, Esposito seemed like the life of the party and apparently he was. In a story that epitomized the togetherness of those Big, Bad Bruins, Esposito had once been playfully kidnapped from Mass General Hospital by his teammates. He suffered torn knee ligaments in the second game of a first round series against the Rangers in 1973, thus contributing to an early exit by the Bs. As the story goes, the team decided it could not hold its break-up dinner at the Branding Iron bar without Esposito so dressed in hospital gear, his teammates surreptitiously wheeled him out of the hospital, still in his johnny, and took him straight to the bar.

Good times like that cant last forever, and they didnt.

On Nov. 7, 1975, GM Harry Sinden traded Esposito and defenseman Carol Vadnais to the New York Rangers in exchange for Brad Park the best defenseman in the league not named Orr and classy centerman Jean Ratelle.

The move kept the Bruins among the elite teams in the league and is widely regarded as a big win for the team, but the trade could not quite lift the Bs back to the heights that it achieved with Esposito roaming the slot.

View post:
Phil Esposito owned the slot like no other Bruin - Boston Herald

Life expectancy in the United States is about 78 years, though longevity is not without medical concerns. As many as one in three Americans will develop malignant cells in their lifetime. While the scientific community has significantly increased their understanding of cancer in recent years and applied that knowledge to treatment, prevention research remains a top priority; however, since cancer is a series of diseases, the exact cause is not always known. Genetics plays an important role, yet so does diet and lifestyle.

Dr. Kevin Dalby, professor of chemical biology and medicinal chemistry, is studying the mechanisms of cancer cells and currently working on cancer drug discovery. His research primarily focuses on developing targeted therapeutics, but he does acknowledge that specific behavioral changes can help lower a persons risk for cancer. The Harvard School of Public Health estimates that 75% of American cancer deaths could be prevented if tactics are adopted on a mass scale.

Below, Dr. Kevin Dalby reviews practical behavioral choices that anyone can take up to help prevent cancer, thus reducing the risk of the emotional and the financial burden inflicted by this crippling disease.

Avoid Tobacco

The correlation between tobacco use and cancer is staggering. In the United States, one out of every five deaths is related to tobacco. Moreover, cigarette smoking accounts for 85-90% of lung cancer deaths and 70% of oral and laryngeal cancer deaths.

Tobacco use (smoking or chewing) is a difficult habit to quit. Still, it could help you as well as those around you (secondhand smoke kills) avoid a future collision with the following cancers: lung, mouth, throat, larynx, pancreas, bladder, cervix, and kidney.

Limit Alcohol

Research has yet to pinpoint exactly how alcohol influences your susceptibility for cancer, but excess use does increase the risk for mouth, throat, liver, colon, rectal, and breast cancer. Men should limit their acholic beverages to two a day and women to one. For context, one drink equates to approximately twelve ounces of beer, five ounces of wine, or one and a half ounces of liquor.

Eat A Healthy Diet

40% of cancers are associated with dietary factors: habits, foods, and nutrients all play a role. The American Cancer Society suggests a daily nutritional regimen consisting of whole grains, fish or poultry, and a variety of vegetables and fruits to lower your risk for cancer. Try to limit red and processed meats, eat fewer sweets, and reduce your intake of saturated fats.

Exercise

Regular physical activity helps you maintain a healthy weight, control blood pressure, and may lower the risk for several types of cancer such as colon, prostate, and even breast cancer. Obesity is especially of paramount importance since it has been linked to 20% of all cancer-related deaths.

Adults should strive to exercise moderately for 150 minutes each week. Alternatively, you can aim for 75 minutes of vigorous activity if that suits your lifestyle better.

Sun Protection

Skin cancer is common but also preventable. To reduce your risk, proportionately apply sunscreen, avoid the sun at midday if possible when its rays are most reliable, cover exposed skin and forgo tanning beds and sunlamps, which are just as dangerous as actual sunlight.

Regular Medical Care

Cancer may not be entirely preventable, but if caught early, your chances of survival improve drastically. Schedule regular checkups with your doctor, be transparent, and ask what tests make sense for you. Depending on your sex, age, and medical history, your doctor may recommend screenings for breast, cervical, colon, lung, or prostate cancer.

About Dr. Kevin Dalby:

Dr. Kevin Dalby has been interested in the why of chemical reactions since he was a student at the University of Cambridge, where he graduated with a Doctor of Philosophy degree in Organic Chemistry. This curiosity has led to his interest in the processes of cell signaling, and ultimately to cancer research. Dr. Dalbys research areas include biochemistry, cancer, cell biology, chemical biology, drug discovery & diagnostics, and enzymology.

See the original post here:
Dr. Kevin Dalby on How to Decrease Your Risk of Developing Cancer - Thrive Global

Qualified Longevity Annuity Contracts (QLACs) are future pension strategies that can be used in your Traditional IRA and some select employer sponsored plans. QLACs were first introduced in 2014 by the IRS and the Treasury Department as a way for people to used their qualified (i.e. IRA) assets to plan for future lifetime income guarantees. Social Security payments were never put in place to be the sole source of income in retirement. Our government (i.e. IRS & Treasury Department) want QLACs to be that additional source as part of your overall income floor guarantees.

QLAC funding rules for 2020 is the lesser of 25% of your total IRA assets or $135,000. If you and your spouse/partner have an Traditional IRA, each of you can own a QLAC and add the other spouse/partner for "Joint Life" income.

QLAC income has to be turned on by age 85. You don't have to defer that long for income to start. It can begin as soon as age 72, and the lifetime income stream can be contractually structured so that 100% of any unused money goes to your listed beneficiaries on the policy when you die. The annuity company is on the hook to pay regardless of how long you live.

Contact Stan The Annuity Man for the best and highest QLAC quotes with all carriers using Stan's proprietary annuity calculators. You can also receive Stan's QLAC Owner's Manual for free and under no obligation, and see a live feed of the best fixed rates for your specific state of residence.

Link:
Qualified Longevity Annuity Contract Pros and Cons - TheStreet

Updated: May 25, 2018:

JD Supra is a legal publishing service that connects experts and their content with broader audiences of professionals, journalists and associations.

This Privacy Policy describes how JD Supra, LLC ("JD Supra" or "we," "us," or "our") collects, uses and shares personal data collected from visitors to our website (located at http://www.jdsupra.com) (our "Website") who view only publicly-available content as well as subscribers to our services (such as our email digests or author tools)(our "Services"). By using our Website and registering for one of our Services, you are agreeing to the terms of this Privacy Policy.

Please note that if you subscribe to one of our Services, you can make choices about how we collect, use and share your information through our Privacy Center under the "My Account" dashboard (available if you are logged into your JD Supra account).

Registration Information. When you register with JD Supra for our Website and Services, either as an author or as a subscriber, you will be asked to provide identifying information to create your JD Supra account ("Registration Data"), such as your:

Other Information: We also collect other information you may voluntarily provide. This may include content you provide for publication. We may also receive your communications with others through our Website and Services (such as contacting an author through our Website) or communications directly with us (such as through email, feedback or other forms or social media). If you are a subscribed user, we will also collect your user preferences, such as the types of articles you would like to read.

Information from third parties (such as, from your employer or LinkedIn): We may also receive information about you from third party sources. For example, your employer may provide your information to us, such as in connection with an article submitted by your employer for publication. If you choose to use LinkedIn to subscribe to our Website and Services, we also collect information related to your LinkedIn account and profile.

Your interactions with our Website and Services: As is true of most websites, we gather certain information automatically. This information includes IP addresses, browser type, Internet service provider (ISP), referring/exit pages, operating system, date/time stamp and clickstream data. We use this information to analyze trends, to administer the Website and our Services, to improve the content and performance of our Website and Services, and to track users' movements around the site. We may also link this automatically-collected data to personal information, for example, to inform authors about who has read their articles. Some of this data is collected through information sent by your web browser. We also use cookies and other tracking technologies to collect this information. To learn more about cookies and other tracking technologies that JD Supra may use on our Website and Services please see our "Cookies Guide" page.

We use the information and data we collect principally in order to provide our Website and Services. More specifically, we may use your personal information to:

JD Supra takes reasonable and appropriate precautions to insure that user information is protected from loss, misuse and unauthorized access, disclosure, alteration and destruction. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. You should keep in mind that no Internet transmission is ever 100% secure or error-free. Where you use log-in credentials (usernames, passwords) on our Website, please remember that it is your responsibility to safeguard them. If you believe that your log-in credentials have been compromised, please contact us at privacy@jdsupra.com.

Our Website and Services are not directed at children under the age of 16 and we do not knowingly collect personal information from children under the age of 16 through our Website and/or Services. If you have reason to believe that a child under the age of 16 has provided personal information to us, please contact us, and we will endeavor to delete that information from our databases.

Our Website and Services may contain links to other websites. The operators of such other websites may collect information about you, including through cookies or other technologies. If you are using our Website or Services and click a link to another site, you will leave our Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We are not responsible for the data collection and use practices of such other sites. This Policy applies solely to the information collected in connection with your use of our Website and Services and does not apply to any practices conducted offline or in connection with any other websites.

JD Supra's principal place of business is in the United States. By subscribing to our website, you expressly consent to your information being processed in the United States.

You can make a request to exercise any of these rights by emailing us at privacy@jdsupra.com or by writing to us at:

You can also manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard.

We will make all practical efforts to respect your wishes. There may be times, however, where we are not able to fulfill your request, for example, if applicable law prohibits our compliance. Please note that JD Supra does not use "automatic decision making" or "profiling" as those terms are defined in the GDPR.

Pursuant to Section 1798.83 of the California Civil Code, our customers who are California residents have the right to request certain information regarding our disclosure of personal information to third parties for their direct marketing purposes.

You can make a request for this information by emailing us at privacy@jdsupra.com or by writing to us at:

Some browsers have incorporated a Do Not Track (DNT) feature. These features, when turned on, send a signal that you prefer that the website you are visiting not collect and use data regarding your online searching and browsing activities. As there is not yet a common understanding on how to interpret the DNT signal, we currently do not respond to DNT signals on our site.

For non-EU/Swiss residents, if you would like to know what personal information we have about you, you can send an e-mail to privacy@jdsupra.com. We will be in contact with you (by mail or otherwise) to verify your identity and provide you the information you request. We will respond within 30 days to your request for access to your personal information. In some cases, we may not be able to remove your personal information, in which case we will let you know if we are unable to do so and why. If you would like to correct or update your personal information, you can manage your profile and subscriptions through our Privacy Center under the "My Account" dashboard. If you would like to delete your account or remove your information from our Website and Services, send an e-mail to privacy@jdsupra.com.

We reserve the right to change this Privacy Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our Privacy Policy will become effective upon posting of the revised policy on the Website. By continuing to use our Website and Services following such changes, you will be deemed to have agreed to such changes.

If you have any questions about this Privacy Policy, the practices of this site, your dealings with our Website or Services, or if you would like to change any of the information you have provided to us, please contact us at: privacy@jdsupra.com.

As with many websites, JD Supra's website (located at http://www.jdsupra.com) (our "Website") and our services (such as our email article digests)(our "Services") use a standard technology called a "cookie" and other similar technologies (such as, pixels and web beacons), which are small data files that are transferred to your computer when you use our Website and Services. These technologies automatically identify your browser whenever you interact with our Website and Services.

We use cookies and other tracking technologies to:

There are different types of cookies and other technologies used our Website, notably:

JD Supra Cookies. We place our own cookies on your computer to track certain information about you while you are using our Website and Services. For example, we place a session cookie on your computer each time you visit our Website. We use these cookies to allow you to log-in to your subscriber account. In addition, through these cookies we are able to collect information about how you use the Website, including what browser you may be using, your IP address, and the URL address you came from upon visiting our Website and the URL you next visit (even if those URLs are not on our Website). We also utilize email web beacons to monitor whether our emails are being delivered and read. We also use these tools to help deliver reader analytics to our authors to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

Analytics/Performance Cookies. JD Supra also uses the following analytic tools to help us analyze the performance of our Website and Services as well as how visitors use our Website and Services:

Facebook, Twitter and other Social Network Cookies. Our content pages allow you to share content appearing on our Website and Services to your social media accounts through the "Like," "Tweet," or similar buttons displayed on such pages. To accomplish this Service, we embed code that such third party social networks provide and that we do not control. These buttons know that you are logged in to your social network account and therefore such social networks could also know that you are viewing the JD Supra Website.

If you would like to change how a browser uses cookies, including blocking or deleting cookies from the JD Supra Website and Services you can do so by changing the settings in your web browser. To control cookies, most browsers allow you to either accept or reject all cookies, only accept certain types of cookies, or prompt you every time a site wishes to save a cookie. It's also easy to delete cookies that are already saved on your device by a browser.

The processes for controlling and deleting cookies vary depending on which browser you use. To find out how to do so with a particular browser, you can use your browser's "Help" function or alternatively, you can visit http://www.aboutcookies.org which explains, step-by-step, how to control and delete cookies in most browsers.

We may update this cookie policy and our Privacy Policy from time-to-time, particularly as technology changes. You can always check this page for the latest version. We may also notify you of changes to our privacy policy by email.

If you have any questions about how we use cookies and other tracking technologies, please contact us at: privacy@jdsupra.com.

Visit link:
Labor Department Issues Guidance on Calculating FLSA Regular Rate - JD Supra

The coronavirus pandemic has forced governments to face excruciating trade-offs. Benefit-cost analysis is a standard framework for making policy trade-offs, and some have suggested that it be used to make policy trade-offs in this pandemic. But benefit-cost analysis is flawed. We can do better.

The spread of this horrific virus has put front and center two types of trade-offs: Risk-income and risk-risk (risk here meaning fatality risk).

Shutting down businesses to enforce social distancing helps to flatten the curve, reducing individuals risks of dying from COVID-19. A flatter curve gives more time for the development of antivirals, the production of needed protective gear and medical devices and ultimately a vaccine. But a shutdown lowers individuals incomes. Income is reduced dramatically during the shutdown itself, and then later too if the shutdown causes a recession. How much should we as a society pay in lower incomes for a given flattening of the curve? This is a risk-income trade-off.

Looming shortages of gloves, masks and ventilators force us to think about rationing. Protective gear reduces fatality risk by lowering infection risk. Should police officers take priority over grocery store clerks in receiving N95 masks? This is a risk-risk trade-off. Medical devices cut down fatality risk among the infected. Which seriously ill patients should be put on ventilators if there arent enough ventilators for all? Should younger patients take priority over older ones? Again, a risk-risk trade-off.

Benefit-cost analysis is widely used by economists, and is now the dominant policy-analysis methodology in the federal government. It works as follows. Each positive or negative impact of a policy is converted into a monetary equivalent by asking how much individuals are willing to pay (for a positive impact) or willing to accept (in exchange for a negative one). The social value of a policy is calculated as the sum of the monetary equivalents for its positive impacts minus the sum of the monetary equivalents for its negative ones.

Valuing fatality risk reduction is nothing new for benefit-cost analysis. The linchpin is the so-called value per statistical life (VSL). An individuals willingness to pay for a risk reduction is just the risk reduction multiplied by VSL. Imagine that Felicias VSL is $6 million. This means that Felicia is willing to pay $6 for a 1-in-1 million risk reduction, $60 for a 1-in-100,000 risk reduction and $600 for a 1-in-10,000 risk reduction.

In principle, VSL varies among individuals. Felicias willingness to pay for risk reduction need not be the same as Victors. Textbook benefit-cost analysis says to convert individuals risk reductions into monetary equivalents using individual-specific VSLs. But this approach has dramatically counterintuitive implications when it comes to risk-risk trade-offs. Because richer individuals tend to have higher VSLs, textbook benefit-cost analysis gives them priority in risk reduction. It implies that richer patients should get priority in receiving ventilators.

The U.S. government in practice deviates from textbook benefit-cost analysis by using a single VSL for everyone (a population average). The number used is generally around $10 million. Benefit-cost analysis with a single VSL avoids giving priority to the rich in risk-risk trade-offs, but it has other difficulties.

First, it fails to give priority to the young in risk-risk tradeoffs. Do we really think that a rationing scheme for ventilators should not differentiate between 30 year-olds and 70 year-olds?

Second, benefit-cost analysis (whether we use individual-specific VSLs or a population average) is completely insensitive to the distribution of income. It surely matters how the costs of a shutdown are distributed across economic groups which in turn depends on the details of the fiscal policies that government puts in place to mitigate those costs. But benefit-cost analysis ignores income distribution; it says that society should be indifferent to whether the costs of a shutdown are borne by the poor, the middle class or the rich.

We can do better. A different methodology is sometimes used in economics, especially for tax policy and climate change. This methodology is called the social welfare function. Rather than translate policy impacts into monetary equivalents, this framework translates them into utilities. An individuals utility is a measure of her strength of preference for various goods (longevity, income, health and so forth). If Abigail prefers one bundle of goods to a second, the first bundle gets a higher utility.

Weve written about how the social-welfare-function approach can be applied to risk policies. In a nutshell, each cohort of similarly situated individuals (for example, age groups subdivided by income) can be seen as facing a lottery over longevity-income bundles. A given governmental policy shifts the lottery that each cohort faces. The simplest, utilitarian, version of this framework assigns a social value to a policy by summing expected utilities across cohorts. A different version, prioritarianism, gives extra weight to the worse off. As weve demonstrated, this methodology has important advantages over benefit-cost analysis when it comes to risk-income and risk-risk trade-offs. It gives preference to the young in risk-risk tradeoffs, but either mitigates (utilitarian) or eliminates (prioritarian) the preference for the rich. Moreover, it is sensitive to the distribution of costs preferring that income losses be borne by those higher up the socioeconomic ladder.

Benefit-cost analysis is a serviceable tool for grappling with trade-offs, but it can be improved on and the social-welfare-function framework shows how.

Matthew Adler is a professor of law at Duke Law School. James Hammitt is a professor of economics and decision sciences at the Harvard T.H. Chan School of Public Health.

Read the original:
A better way to grapple with benefit-cost trade-offs in a pandemic | TheHill - The Hill

USA TODAY Sports' Nate Davis breaks down the grades of some NFL teams after an eventful free agency period. USA TODAY

Bill Belichick still isn't in any mood to talk about Tom Brady.

Monday, the New England Patriots coach held a pre-draft conference call, the first time he'd spoken to reporters since Jan. 5 the day after the perennial AFC East champs' wild-card loss to the Tennessee Titans.

That playoff ouster also will represent the final time Brady, now a member of the Tampa Bay Buccaneers, suited up for the team that he led to nine Super Bowls and six Lombardi Trophies after New England drafted him in 2000.

"It would be of course impossible to sum up everything Tom did in 20 years into a comment, then or now," Belichick said Monday, according to The Boston Globe.

"Right now we're moving forward and focused on the draft here on this call."

For the first time since 2000, Tom Brady (12) and Patriots coach Bill Belichick won't be on the same sideline.(Photo: Greg M. Cooper, USA TODAY Sports)

Back in January, Belichick Mr. "We're on to Cincinnati," his mantra intended to keep the Patriots always looking ahead wanted to talk about the loss to the Titans, not Brady's future. Nowit's all about the draft, not reflecting on Brady's contributions over two stellar decades in Foxborough.

In between, on March 17, Belichick did say this of Brady, after he announced his intention to leave the Patriots: "Tom and I will always have a great relationship built on love, admiration, respect and appreciation.Toms success as a player and his character as a person are exceptional.Nothing about the end of Toms Patriots career changes how unfathomably spectacular it was.With his relentless competitiveness and longevity, he earned everyones adoration and will be celebrated forever.It has been a privilege to coach Tom Brady for 20 years.

NFL draft 2020 rankings: Chase Young, Joe Burrow headline top 50 rankings

Boom or bust: Jordan Love, Justin Herbert among 15 riskiest prospects in 2020 NFL draft

Who should pick a QB?: Recommendations for all 32 teams

"Sometimes in life, it takes some time to pass before truly appreciating something or someone but that has not been the case with Tom.He is a special person and the greatest quarterback of all-time."

Yet now, Belichick is unsurprisingly planning for life after Brady, second-year quarterback Jarrett Stidham currently the only quarterback listed on the team's roster. Veteran Brian Hoyer has agreed to return to the team in 2020, however his signing has yet to be officially announced.

Stidham threw only four passes in three brief appearances as a rookie but seems likely to get first crack at taking over for TB12.

The Patriots hold the 23rd pick of next week's NFL draft but don't pick again until No. 87, deep in the third round. Among this year's top passing prospects, Oregon'sJustin Herbert and Utah State'sJordan Love are the most realistic targets, but either might require a move up in Round 1.

Predictably, Belichick spoke in generalities about this year's incoming crop of passers, which also includesincludes LSU's Joe Burrow, Alabama'sTua Tagovailoa, Oklahoma'sJalen Hurts, Georgia'sJake Fromm and Washington'sJacob Eason.

Burrow is expected to be the first pick off the board to the Bengals, whileTagovailoa is widely projected as a top-five selection.

***

Follow USA TODAY Sports' Nate Davis on Twitter @ByNateDavis

Autoplay

Show Thumbnails

Show Captions

Read more here:
Bill Belichick on Tom Brady: Patriots 'moving forward and focused on the draft' - USA TODAY

The quality of a romantic comedy depends almost entirely on how much we root for the central couple. But sometimes, even in a good film, the couple falls short. Below, I have given scientifically calculated percentages for the likelihood that these couples stayed (happily!) together after the events of the film. Sony Pictures Releasing

Don't ask me how I got these numbers. Let's just say I crunched them. That sounds legitimate.

They definitely had a hot fling for a bit, but no WAY did they end up together. He was SUCH a dick to her and she didn't deserve that.

Cady and Aaron barely had one real conversation the whole movie. She only liked him because he was hot, and it was unclear why he liked her. Plus, he went off to college the next year! I doubt they stayed together past a few months of college.

Sandy totally changed herself for Danny!!! Even if they did last, Sandy would've grown to resent him for this. She probably sang an epic breakup ballad and dumped his ass.

Oh boy, I'm going to get a lot of hate for this one, but...Jake sucked. Their relationship sucked. There was way too much fighting and there was a REASON they were getting divorced. If it did last, it was a very unhappy marriage.

They might have stayed together, but I don't think they were happy. Their relationship started with an inherent power imbalance, and I don't think that would ever really change.

Like Mean Girls, this is another one where the characters really didn't know each other. AT ALL. Did they even have a conversation? I find it unlikely they stayed together, but since we really know nothing about them as a couple, it's hard to say.

They shared an emotional bond, but Austin was kind of a fuckboy and Sam deserved better. But they did go to the same college, so maybe they made it work there. I'm doubtful, though.

I don't know how they fell in love, because neither of them were themselves for pretty much the entirety of the movie. I feel like they just got caught up in the drama and passion, but who knows. Maybe they made it work once they revealed their true selves.

I'm actually a little unsure about both couples in this movie, but especially Amanda and Graham. They clearly had great chemistry and a good connection, but all the reasons they decided not to be together (before Amanda changed her mind) were really valid. I'm just not sure they would've been able to work out the logistics. I feel like the passion would start to fade.

This is such a fun movie, and I love Margaret and Andrew together, but I'm not sure they went the distance. I'm sure it put a strain on their relationship to get married before they really started dating, and I'm just not sure they were able to get over the power dynamic of their past. However, I do believe Andrew made Margaret better, and I rooted for them for sure!

I love Amy and Aaron together, and by the end of the film Amy had really stepped up and fought for that relationship. But I can't be sure she didn't fall back into old habits. I hope they ended up together forever, but it's hard to tell!

Look, this love story spanned DECADES! Even Will's daughter rooted for them!! He was so enamored with her and still thought of her so many years later. I truly believe their love could go the distance!! However, April was scared of commitment, so I can't say with certainty.

I don't believe in them quite as much as Allegra and Albert, because I feel like there were more lies here. But I also loved them together and I loved that Sara was really strong and independent and said what she felt. I think they were good for each other, and I'm hoping they made it work!!

First of all, Jamie and Dylan were really upfront with each other and had really great communication about sex, which we don't usually see in rom-coms. So we know that aspect of the relationship was good! PLUS, their relationship was built on an already strong friendship! I could see them as partners forever for sure.

I TOTALLY got why Scarlet wanted a divorce. But after turning into a teenager and discovering that even if he could go back, he'd make the same decisions, he learned to truly appreciate his wife again. I'm pretty sure they lived happily ever after!

Look, I know their whole relationship was sort of built on a lie since Albert hired Hitch to help him, but in the end it was revealed Allegra was just as dorky as him and loved all the things about him that Hitch told him to hide. They were SO CUTE together and I was so happy to see them get married at the end. I feel like they could entertain each other for decades.

Nick was willing to leave his family behind for Rachel, but Rachel wouldn't let him because she didn't want to tear apart his family. She truly fought for him, but in the end she wanted what was best. I was so glad they ended up together and I believe they stayed together for sure!

This movie tore my heart out!!! I was SO happy Jenna was able to go back and make things right with Matty so that they ended up together in the end. Jenna really truly loved Matty and just wanted him to be happy so much so that she was able to let him go!!! And Matty was amazing from the start. They were perfect for each other!!

Tell me that Hannah and Jacob were not MEANT FOR EACH OTHER!!!!! They are my fave rom-com couple EVER because they knew how to laugh together, and I truly believe they made each other better.

Apr. 10, 2020, at 19:02 PM

We referred to Albert from Hitch as Alfred a couple times. Oops!

Originally posted here:
I Have Some Strong Opinions On The Longevity Of These Rom-Com Couples So I Ranked Them - BuzzFeed

In two weeks, Larryand Mary Centolawill celebrate their marriage of 74 years, marking a joyous occasion amidst a worsening pandemic that has upended American life.

Its so sad. So many people have died, Mary, 94, said. I always count our blessings. I wake up in the morning, and I say: Thank you, God, for blessing us with another day of good health.

Like millions of otherLong Islanders, the New Hyde Park couple is hunkering down at home to slow the spread of the coronavirus. Neighbors are helping the Centolas, whose ages make them among the most susceptible to COVID-19, get groceries and necessities.

This year, the celebration will be small.

We will just toast to each other and wish each other another happy year, Mary said. I dont think I have any champagne left. So it will have to be wine.

As the nations annual divorce rate hovers between 40%and 50%, the Centolas nearly three-quarter-century marriage has left many wondering about the secret to their longevity, including North Hempstead Town Clerk Wayne Wink,who asked the coupleabout it during a Valentines Day celebration.

Mary, a devoutCatholic, attributed it to a lot of patience, love, understanding and faith.

Larry, 95, recounted the day they met in 1945, at a department store in Jamaica, Queens, where his future wife worked. He fought in World War IIand was on convalescent furlough when he accompanieda friend visiting his girlfriend at work.

Get the latest breaking news as it happens.

By clicking Sign up, you agree to our privacy policy.

I was very lucky to meet Mary by mistake, Larry told dozens of couples at the North Hempstead Town celebration. When I talked to herI said to myself: Shes a nice girl. So I said: Would you like to go for coffee? So from coffee, we were married.

The couple wed in a Queens church on April 28, 1946. Three years later, they moved into their home. Mary worked for the New York Telephone Company for 25 years, and Larry wasa jeweler in Manhattan for 45 years. They have no children.

They are not transient,said Denise Siciliano, Marys niece, whom the Centolas regard as their daughter.Im in my third house. They dont want to upset their applecart. Its their routine.

Siciliano, 70, of Westlake Village, California, went through a divorce in her 20s and said she believes her aunt and uncle are well-suited for each other.

When you know its right, its right, said Siciliano, who remarried and has been wed tohusbandArthurfor 45 years. Each of them are everything to each other. And its been like that since they got married.

The Centolas said they dont know thatthey have a secret to the longevity of their union. Larry said they enjoy each others company. Mary said she loves his carefree attitude and humor, and recalled a joke he told about hishospital stay after being bombed out of a foxhole in Germany.

He was knocked out unconscious for six days, Mary said.He woke up on Christmas Day and heard people singing. He thought he was in heaven.

Lasting love

See original here:
Larry & Mary + love and marriage = 74 - Newsday